Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc.

The Company now concentrates its activities in the field of oncology through the development of Chimeric Antigen Receptor T-cell immunotherapy products generated through its allogeneic CAR-T platform, both on its own as well as in partnership with is a biotechnology company focused on applications of human embryonic stem cell based products and ... (more)

http://ift.tt/1oEAca1